51. Synergistic enzymatic and bioorthogonal reactions for selective prodrug activation in living systems
- Author
-
Feng Lin, Yanpu Wang, Ye Liu, Xinyuan Fan, Xingyu Jiang, Yuan Gao, Zhaofei Liu, Peng Chen, and Qingxin Yao
- Subjects
Drug-Related Side Effects and Adverse Reactions ,Cell Survival ,medicine.medical_treatment ,Science ,General Physics and Astronomy ,Mice, Nude ,02 engineering and technology ,Pharmacology ,010402 general chemistry ,01 natural sciences ,General Biochemistry, Genetics and Molecular Biology ,Article ,Cell Line ,Mice ,Pharmacokinetics ,In vivo ,Neoplasms ,medicine ,Human Umbilical Vein Endothelial Cells ,Animals ,Humans ,Prodrugs ,Drug reaction ,lcsh:Science ,chemistry.chemical_classification ,Tomography, Emission-Computed, Single-Photon ,Chemotherapy ,Multidisciplinary ,Chemistry ,General Chemistry ,Prodrug ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,Enzyme ,Cancer cell ,Female ,lcsh:Q ,Bioorthogonal chemistry ,0210 nano-technology ,HeLa Cells - Abstract
Adverse drug reactions (ADRs) restrict the maximum doses applicable in chemotherapy, which leads to failure in cancer treatment. Various approaches, including nano-drug and prodrug strategies aimed at reducing ADRs, have been developed, but these strategies have their own pitfalls. A renovated strategy for ADR reduction is urgently needed. Here, we employ an enzymatic supramolecular self-assembly process to accumulate a bioorthogonal decaging reaction trigger inside targeted cancer cells, enabling spatiotemporally controlled, synergistic prodrug activation. The bioorthogonally activated prodrug exhibits significantly enhanced potency against cancer cells compared with normal cells. This prodrug activation strategy further demonstrates high tumour inhibition efficacy with satisfactory biocompatibility, pharmacokinetics, and safety in vivo. We envision that integration of enzymatic and bioorthogonal reactions will serve as a general small-molecule-based strategy for alleviation of ADRs in chemotherapy., The side effects of cancer drugs limit their utility. Here, the authors developed a method in which an inactive (prodrug) version of the cancer drug doxorubicin enters tumour cells and then gets activated inside the cells upon a trigger facilitated by enzyme-instructed supramolecular self-assembly.
- Published
- 2018